169 results about "Tumor recurrence" patented technology

The invention discloses a tumor recurrence risk prediction method and system based on electronic medical record data, and relates to the field of electronic medical record data processing and analys.The historical electronic medical record data are processed in a structured mode, a recurrence risk mapping model is established, individualized recurrence risk assessment can be achieved based on multi-dimensional features, and the tumor recurrence risk prediction accuracy is improved. The subjective judgment error is obviously reduced; a risk level layering mechanism can automatically distinguish patients needing emergency intervention and conventional monitoring, excessive medical treatment or delayed treatment is avoided, and the method is particularly suitable for chronic diseases such as tumors needing long-term management; through periodic marker measurement and risk level feedback, closed-loop management of evaluation-intervention-re-evaluation is formed, and the requirement for continuous optimization of clinical diagnosis and treatment is met; in addition, through preprocessing, the preprocessed multi-dimensional features can be directly called subsequently, and repeated data cleaning work is avoided.

The invention discloses a recurrence-resistant cell strain for colorectal cancer large segmentation radiotherapy and application, and relates to the technical field of cell biology. The colorectal cancer large segmentation radiotherapy recurrence-resistant cell strain is preserved in the China Center for Type Culture Collection on January 2, 2025, the preservation address is Wuhan University, Wuhan, China, and the preservation number is CCTCC NO: C202533. By constructing the colorectal cancer large segmentation radiotherapy recurrence-resistant cell strain, a new biological material is provided for studying the radiotherapy recurrence-resistant colorectal cancer. The cell strain is screened in a mouse body with a sound immune system, has better physiological correlation, and is beneficial to research on the influence of an immune microenvironment on tumor cell radiotherapy resistance and the remodeling effect of radiotherapy resistant cells on the immune microenvironment. The cell strain can also monitor tumor recurrence after radiotherapy in real time through fluorescence imaging.

The invention discloses a zinc-selenium doped white calcium stone injectable hydrogel for treating melanoma and a preparation method of the zinc-selenium doped white calcium stone injectable hydrogel. The preparation method comprises the following steps: 1, preparing hydrophilic zinc-selenium doped white calcium stone; 2, preparing oxidized sodium alginate; and (3) dispersing the hydrophilic zinc-selenium-doped white phosphorus calcium stone into the oxidized sodium alginate solution, adding the carboxymethyl chitosan solution, and uniformly mixing to obtain the zinc-selenium-doped white phosphorus calcium stone injectable hydrogel for treating melanoma. The injectable hydrogel prepared by the invention has good injectability, self-healing property and biocompatibility, and is suitable for tumor wound models with any shape and depth; the composition has good effects of promoting normal cell proliferation and inhibiting tumor cell growth, and can be used for tumor postoperative treatment to inhibit tumor recurrence and promote surgical defective tissue repair.

A computer implemented method of distinguishing tumor progression from treatment-related necrosis in digital images of a subject implements a multimodal deep learning architecture from MRI data of a selected anatomical portion of the subject, such as a brain, and corresponding dPET data for the subject with a tracer applied to the anatomical portion of the subject. The computer stores co-registered MRI data frames with dPET data frames as three dimensional (3D) parametric PET maps to identify multi-modal image features of segmented tumor data. A convolutional neural network uses MRI data and selected multi-modal image features as inputs and the computer concatenates respective output latent feature vectors from the respective sections of the at least one CNN. Feeding concatenated feature vectors to fully connected layers of the multimodal architecture distinguishes tumor progression from treatment-related necrosis of the anatomical portion of the subject.

The invention relates to a multiple myeloma model with extramedullary lesion as well as a construction method and application thereof. The multiple myeloma model is obtained by injecting bone marrow mononuclear cells (BMMC) of a multiple myeloma patient into an hIL-6NSG mouse. The invention provides a new model of multiple myeloma with extramedullary lesion, which not only is beneficial to research on gene pathway and mechanism of the multiple myeloma, but also lays a foundation for research on tumor recurrence, preclinical drug screening, effect evaluation and the like, and has great significance in promoting disease healing.

The application provides a radionuclide nanohydrogel microneedle and a preparation method and application thereof, and belongs to the field of nanobiomedicine. 32 P-labeled calcium phosphate, which is formed by a biomimetic reaction of Ag2S@Ca 32 P nanoparticles, and a base layer which is a base matrix and comprises hyaluronic acid 32 P nanohydrogel microneedle can release Ag2S nanoparticles in response to a weakly acidic tumor environment, and under the irradiation of near-infrared light, the photothermal conversion efficiency can effectively kill bacteria, effectively improve the tumor hypoxic environment, enhance the treatment effect of radionuclides, play an antibacterial and wound healing promoting role in melanoma defect repair, and maximize the inhibition of tumor growth and tumor recurrence.

The invention relates to the technical field of biological medicine, and provides a Chinese herbal medicine vesicle-LNP hybrid tumor mRNA vaccine and application thereof. The tumor mRNA vaccine disclosed by the invention is obtained by hybridizing Chinese herbal medicine nano-vesicles and lipid nano-particles loaded with tumor antigen mRNA. According to the invention, the characteristic of good biocompatibility of Chinese herbal medicines is utilized, so that the safety risk of the cationic lipid carrier is reduced. By combining the characteristics of Chinese herbal medicines, the nano-vesicles are extracted, so that the LNP is promoted to more effectively target antigen-presenting cells, the uptake level of the antigen-presenting cells is promoted, the phagocytosis of mRNA is enhanced, and the targeting and transcriptional expression level of mRNA can be enhanced. Finally, the Chinese herbal medicine nano vesicle-LNP hybrid tumor mRNA vaccine can strengthen the curative effects of inhibiting tumor progression, tumor recurrence and tumor metastasis after the tumor mRNA vaccine is inoculated, and a path is opened up for the combination of the tumor mRNA vaccine and richer immunotherapy means.

The invention relates to the technical field of biomedical engineering and drug delivery, and particularly discloses a novel targeted drug delivery system based on rose fruit extracellular vesicles, which comprises the following steps: preparing rose fruit source extracellular vesicles; preparing a medicine carrying vesicle; preparing targeted modified drug-loaded vesicles; according to the application disclosed by the invention, a stem related pathway is specifically down-regulated through the components of the rose fruits, and meanwhile, conventional tumor cells are killed by using adriamycin, so that a complementary treatment mechanism is formed, and the tumor recurrence risk is fundamentally reduced. The phenylboronic acid group of DSPE-PEG-PBA is used for specifically recognizing sialic acid over-expressed on the surface of a tumor cell, so that the enrichment of the medicine in tumor tissues is remarkably improved, and meanwhile, the distribution of normal tissues is reduced. By means of the natural biocompatibility and low immunogenicity of the RHNVs and in combination with the long circulation characteristic of a PEG chain, the delivery efficiency is guaranteed, the systemic toxicity is reduced to the maximum extent, and particularly the cardiotoxicity and myelosuppression of adriamycin are relieved.

The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.

The present disclosure relates to chimeric antigen receptor cells targeting ROBO1, in particular, enhanced CAR-T cells and CAR-NK cells targeting ROBO1, and preparation and application thereof. The cells can stably expressing CAR elements, while secreting extracellular domain molecules expressing PD-1 protein or mutants thereof, and thus may block PD-11PD-L1 molecular interaction. It has been found through animal experiments that the cells have very good anti-tumor effects, and the above-mentioned cells can significantly reduce tumor recurrence and improve the survival rate compared with the conventional ROBO1-targeted CAR modified cells.

The invention discloses a manganese urate material, a gel preparation and application thereof, and relates to the technical field of gel preparations. The manganese urate material provided by the invention can enhance anti-tumor immune response, and has good application prospects of adjuvants, vaccines and medicines. Besides, the invention also provides a gel preparation, the preparation is a multifunctional temperature-sensitive hydrogel preparation taking poloxamer as a matrix, and the preparation is combined with artesunate, adriamycin, uric acid and manganese to realize efficient treatment of various tumors such as breast cancer and inhibit postoperative recurrence of the tumors.

The invention relates to the technical field of application of glehnia littoralis, in particular to application of glehnia littoralis in preparation of drugs, and discloses new application of glehnia littoralis in preparation of drugs for preventing postoperative recurrence and metastasis of tumors, and the glehnia littoralis is applied to preparation of drugs for preventing postoperative recurrence and metastasis of tumors under the concentration of not causing cytotoxicity and toxic and side effects. Through multiple key steps of intervening tumor metastasis, including inhibition of adhesion of circulating tumor cells on vascular endothelial cells, inhibition of EMT transformation of the circulating tumor cells, inhibition of trans-endothelial migration of the circulating tumor cells and the like, the effect of preventing tumor metastasis or treating tumors is achieved, and meanwhile, the activity of immune cells is improved; the traditional Chinese medicine composition has the advantages of being capable of enhancing the killing ability of immune cells to circulating tumor cells, prolonging the lifetime, having extremely high safety, and solving the problems that the immune system and the rehabilitation ability are damaged in anti-cancer treatment by traditional medicines, the traditional cancer prevention and treatment strategy is limited and the like.

The application discloses a tumor recurrence risk prediction method and system based on electronic medical record data, relates to the field of electronic medical record data processing and analysis, and can realize individualized recurrence risk assessment based on multidimensional characteristics, significantly reduces subjective judgment errors, and establishes a recurrence risk mapping model through structured processing of historical electronic medical record data; a risk grade stratification mechanism can automatically distinguish patients who need emergency intervention from patients who need routine monitoring, avoids excessive medical treatment or delayed treatment, and is especially suitable for chronic diseases such as tumors that need long-term management; through periodic marker measurement and risk grade feedback, a closed-loop management of 'assessment-intervention-reassessment' is formed, meeting the needs of continuous optimization of clinical diagnosis and treatment; in addition, through preprocessing, multidimensional characteristics after preprocessing can be directly called in the subsequent process, and repeated data cleaning work is avoided.

The invention provides a tumor radiotherapy rehabilitation abnormity early warning method and system, and relates to the technical field of medical data analysis, and the method comprises the steps: obtaining a first tumor CT image and first image feature information thereof, first focus region detection information and first focus feature information after the first reexamination after tumor radiotherapy treatment; and after the kth review, obtaining a second tumor CT image and second image feature information thereof, and obtaining second focus area detection information and second focus feature information in combination with the first focus feature information so as to determine abnormal early warning information. According to the method and the device, the tumor CT image obtained after each review can be processed by using the anomaly recognition model, and during processing, the tumor CT image obtained during the previous review is combined for comprehensive analysis, and the condition and change of a focus can be analyzed, so that the comprehensiveness and the accuracy of analysis are improved, the distinguishing accuracy of pseudomorphism and tumor recurrence is improved, and the success rate of tumor review is improved. And the early warning accuracy is improved.

This invention relates to the field of biotechnology, specifically to a TruC-T cell that secretes and expresses IL-7 and PF4 to enhance anti-tumor activity and targets uPAR, and its application. Interleukin-7 (IL-7) can effectively promote the development, survival, and proliferation of T cells, while platelet factor 4 (PF4 / CXCL4) can regulate the immune response and chemotactically attract leukocytes to specific sites; the synergistic effect of the two can enhance the anti-tumor function and persistence of T cells. Meanwhile, urokinase-type plasminogen activator receptor (uPAR) is highly expressed in various solid tumors and hematological malignancies, making it an ideal target for tumor therapy; TruC-T cells targeting uPAR can precisely act on tumor tissue, and combined with the immune-enhancing effects of IL-7 and PF4, can significantly improve the efficacy of anti-tumor immune responses, prolong the duration of therapeutic effects, and reduce tumor recurrence.

The application discloses a novel AIE photosensitizer and a preparation method and application thereof. The AIE photosensitizer of the application comprises TDQ shown in the following structural formula, has superior photo-thermal conversion performance and photodynamic performance, and can be used for preparing a tumor diagnosis reagent or a tumor treatment drug. The co-loading liposome of TDQ and a senescence-inducing molecule (Ali) can be used as a multi-modal light diagnosis and treatment agent to realize efficient delivery of drugs to tumor tissues, and the photo-thermal therapy and the photodynamic therapy based on TDQ not only induce cell apoptosis through oxidative stress and mitochondrial dysfunction, but also trigger cancer cell senescence and promote the secretion of SASPs, so that the anti-tumor immunity is significantly enhanced, and finally the growth of primary tumors, tumor recurrence and re-metastasis are inhibited. The material of the application has simple preparation process, low cost, and is suitable for scale production and clinical medical use.

The invention belongs to the technical field of biological medicine, and particularly relates to application of an anti-HIV drug in inhibition of non-small cell lung cancer drug resistance. The invention finds that the combined use of the anti-HIV drug and EGFR-TKI can effectively and specifically target the MRD drug-resistant cells, inhibit the formation of the MRD drug-resistant cells, significantly improve the curative effect of EGFR-TKI and delay tumor recurrence.

The present invention relates to an oncolytic adenovirus capable of co-expressing interleukin-12 and a C-met-inhibiting oligonucleotide; and an antitumor immune-boosting composition and anticancer composition comprising the oncolytic adenovirus. The present invention has first identified an adenovirus system having simultaneous effects of IL-12 expression and C-met inhibition in cancer gene treatment. The adenovirus system of the present invention is capable of inhibiting C-met while expressing interleukin-12, thereby restoring immune functions in a tumor environment to enhance anticancer effects such as the inhibition of tumor recurrence and tumor growth and to inhibit tumor migration. Accordingly, the adenovirus system of the present invention can be effectively used in the treatment of cancer.

The application discloses a bispecific chimeric antigen receptor targeting HER2 and HLA-G and application thereof, and belongs to the tumor immunotherapy field.The chimeric antigen receptor comprises an extracellular domain, a hinge domain, a transmembrane domain and at least one intracellular domain, and the extracellular domain comprises an anti-HER2 single-chain antibody and an anti-HLA-G single-chain antibody.The bispecific chimeric antigen receptor of the application can effectively improve the killing signal of immune cells, and can effectively avoid the inhibition of the immunosuppressive signal on the function of immune cells, thereby delaying the recurrence of tumors, and has very important clinical application value.

Disclosed herein are macrolide compounds having senescent cell elimination activity. These compounds selectively target senescent cells and can be used to reduce or eradicate senescent cells in a subject's body and / or delay the onset of aging. These compounds also inhibit the proliferation of cancer stem cells and can be used to treat cancer, particularly to inhibit the proliferation of cancer stem cells that cause metastasis and tumor recurrence.

A pharmaceutical composition comprises an oncolytic virus and odontogenic stem cells. At least a portion of the oncolytic virus is contained within the odontogenic stem cells. The pharmaceutical composition treats tumors, prevents tumor recurrence or inhibits tumor metastasis through intraperitoneal administration and intratumor injection.

The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.

The application belongs to the technical field of biomedical materials, and discloses a acutine-chitosan / calcium carbonate hemostatic sponge as well as a preparation method and application thereof. The acutine and chitosan are condensed to obtain acutine-chitosan, and then the acutine-chitosan is reacted with sodium carbonate, calcium hydroxide and urea to form the acutine-chitosan / calcium carbonate hemostatic sponge. In-vivo and in-vitro experiments verify that the sponge can be used for hemostasis and antibiosis, and due to the pH sensitivity of the acutine-chitosan, the acutine can be intelligently controlled to be released under acidic conditions (cancer acidic environment), so that the sponge can be used for rapid hemostasis during cancer surgery, and also helps to prevent recurrence of liver cancer after surgery. Therefore, the multifunctional acutine-chitosan / calcium carbonate hemostatic sponge of the application provides a 'one-stop' synergistic strategy for intraoperative hemostasis and postoperative prevention of tumor recurrence of liver cancer, and has great clinical application potential.

The application provides a magnetic response composite hydrogel for integrated repair of bone defects and a preparation method thereof, and belongs to the technical field of medical materials. The composite hydrogel can efficiently inhibit tumor cell activity under the time sequence regulation of an external alternating magnetic field, and then provide a suitable microenvironment and key components for bone tissue regeneration, so that signal conversion and function connection from tumor killing to bone repair are realized. The material has good injectability and self-healing ability, can minimally invasively fill irregular defects, and has significant advantages in simplifying the clinical treatment procedure, shortening the treatment course, reducing the risk of tumor recurrence and improving the repair quality, and provides a new and integrated treatment strategy for tumor-related bone defects.

The present invention discloses a microenvironment-responsive micelle, a preparation method thereof, and an application thereof in the preparation of a drug for inhibiting ovarian cancer recurrence, relating to the technical field of pharmaceutical preparations. The preparation method comprises the following steps: dissolving polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, D-α-tocopheryl polyethylene glycol succinate, DSPE-PEG 2000 , DSPE-PEG 2000 -TK-PEG 5000 , paclitaxel, curcumol, and DSPE-PEG 2000 -FSHB in a solvent, transferring the solution to a rotary evaporation device, evaporating to remove the solvent to form a thin film; hydrating the thin film with a PBS solution, and then performing an extrusion treatment with a microporous membrane to obtain the microenvironment-responsive micelle. The microenvironment-responsive micelle can enhance the uptake of drugs by cancer stem cells, enabling the drugs to play a role in inhibiting tumor recurrence in vivo.

The invention belongs to the technical field of biological detection and treatment, and particularly relates to an innovative application of novel circRNA: circM-TMEFF1 in diagnosis and treatment of hepatocellular carcinoma. The circM-TMEFF1 forms a ring in hepatocellular carcinoma cells, and the specificity of the circM-TMEFF1 is in low expression. The invention specifically provides application of circM-TMEFF1 as a marker in preparation of a hepatocellular carcinoma diagnosis or prognosis kit, and compared with a normal control person, the expression quantity of circM-TMEFF1 in hepatocellular carcinoma tissues and tumor recurrent tissues is remarkably reduced, so that circM-TMEFF1 can be used as a biomarker for diagnosis and prognosis of hepatocellular carcinoma. Besides, promotion of circM-TMEFF1 expression can effectively inhibit proliferation and growth of hepatocellular carcinoma cell lines, a new target is provided for improvement of treatment of hepatocellular carcinoma, and the circM-TMEFF1 has great clinical value.

The invention provides a personalized cancer vaccine based on apoptosis vesicles and a preparation method and application thereof, and belongs to the technical field of biological medicine, the personalized cancer vaccine comprises apoptosis vesicles, an immunologic stimulant and a biocompatibility carrier; the apoptosis vesicles are extracellular vesicles generated after tumor cells are subjected to apoptosis induction; the biocompatible carrier is a modified chitosan hydrogel, and the biocompatible carrier is a modified chitosan hydrogel; the immunologic stimulant is loaded in the apoptosis vesicle, and the apoptosis vesicle loaded with the immunologic stimulant is embedded into the modified chitosan hydrogel. According to the invention, apoptosis vesicles generated by induction of tumor cells of a patient are taken as a core, the apoptosis vesicles have a natural tumor antigen library and a strong immune activation capability, and personalized precise treatment can be realized; meanwhile, the invention provides a preparation method and application in postoperative tumor recurrence prevention and treatment, and provides technical support for clinical transformation.

The invention provides a degradable flexible electronic device which is applied to tumor postoperative monitoring and comprises a substrate layer, an electrode layer, an electrode modification layer and a packaging layer. The electrode layer is formed on the substrate layer in a patterned structure and forms a plurality of groups of electrode arrays, and a working electrode is configured in each group of electrode array; the electrode modification layers are located on all the working electrodes, aptamers are assembled in the electrode modification layers, and the electrode modification layers are used for being in targeted combination with tumor target markers in the to-be-monitored area after the tumor operation and reacting, changing the interface impedance of the working electrodes and transmitting interface impedance signals of the working electrodes to an external receiving device; the external receiving device monitors the interface impedance signal state based on the interface impedance signal of the working electrode so as to obtain information about whether tumor recurrence and / or metastasis exist in the to-be-monitored area after the tumor operation; the substrate layer, the electrode layer and the packaging layer are all made of degradable materials. The invention further provides a preparation method of the degradable flexible electronic device and a monitoring system.

A novel biomimetic nano-sphere M@P-WI includes PLGA nanoparticles and the membrane of breast cancer EO771 cells. The PLGA nanoparticles are encapsulated within the membrane of breast cancer EO771 cells, and IR780 and DDR2 inhibitor WRG-28 are embedded in the PLGA nanoparticles. A method for preparing and applying the novel biomimetic nano-sphere M@P-WI is also provided. The method utilizes the aforementioned novel biomimetic nano-sphere M@P-WI, to trigger the conversion of light into heat energy upon near-infrared laser irradiation. This “burns” the tumor and induces specific immune responses within the body, inhibiting tumor recurrence and metastasis. Under the action of WRG-28, it promotes apoptosis of cancer-associated fibroblasts (CAF), reduces the remodeling of tumor extracellular matrix microenvironment, enhances the distribution of nanomaterials within the tumor, and restricts the invasiveness of breast cancer cells. With laser irradiation, the photosensitizer exhibits its maximum efficacy, achieving complete elimination of TNBC rich in extracellular matrix.